| CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma B Coiffier, E Lepage, J Brière, R Herbrecht, H Tilly, R Bouabdallah, ... New England Journal of Medicine 346 (4), 235-242, 2002 | 6716 | 2002 |
| Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe … B Coiffier, C Thieblemont, E Van Den Neste, G Lepeu, I Plantier, ... Blood, The Journal of the American Society of Hematology 116 (12), 2040-2045, 2010 | 1656 | 2010 |
| Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study M Crump, SS Neelapu, U Farooq, E Van Den Neste, J Kuruvilla, J Westin, ... Blood, The Journal of the American Society of Hematology 130 (16), 1800-1808, 2017 | 1468 | 2017 |
| Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease C Fermé, H Eghbali, JH Meerwaldt, C Rieux, J Bosq, F Berger, T Girinsky, ... New England Journal of Medicine 357 (19), 1916-1927, 2007 | 562 | 2007 |
| Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma S Le Gouill, C Thieblemont, L Oberic, A Moreau, K Bouabdallah, ... New England Journal of Medicine 377 (13), 1250-1260, 2017 | 408 | 2017 |
| microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification B Stamatopoulos, N Meuleman, B Haibe-Kains, P Saussoy, ... Blood, The Journal of the American Society of Hematology 113 (21), 5237-5245, 2009 | 380 | 2009 |
| Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study E Van Den Neste, N Schmitz, N Mounier, D Gill, D Linch, M Trneny, ... Bone marrow transplantation 51 (1), 51-57, 2016 | 286 | 2016 |
| Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial N Kalakonda, M Maerevoet, F Cavallo, G Follows, A Goy, JSP Vermaat, ... The Lancet Haematology 7 (7), e511-e522, 2020 | 267 | 2020 |
| No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long … I Demeestere, P Brice, FA Peccatori, A Kentos, J Dupuis, P Zachee, ... Journal of Clinical Oncology 34 (22), 2568-2574, 2016 | 236 | 2016 |
| High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia M Pasquet, C Bellanné-Chantelot, S Tavitian, N Prade, B Beaupain, ... Blood, The Journal of the American Society of Hematology 121 (5), 822-829, 2013 | 236 | 2013 |
| Positron emission tomography–computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset … J Trotman, M Fournier, T Lamy, JF Seymour, A Sonet, A Janikova, ... Journal of Clinical Oncology 29 (23), 3194-3200, 2011 | 233 | 2011 |
| Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP … RU Trappe, D Dierickx, H Zimmermann, F Morschhauser, P Mollee, ... Journal of Clinical Oncology 35 (5), 536-543, 2017 | 198 | 2017 |
| How I manage patients with relapsed/refractory diffuse large B cell lymphoma C Gisselbrecht, E Van Den Neste British journal of haematology 182 (5), 633-643, 2018 | 185 | 2018 |
| A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy E Bachy, MJ Maurer, TM Habermann, B Gelas-Dore, D Maucort-Boulch, ... Blood, The Journal of the American Society of Hematology 132 (1), 49-58, 2018 | 182 | 2018 |
| Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients J Donadieu, M Lamant, C Fieschi, FS de Fontbrune, A Caye, M Ouachee, ... haematologica 103 (8), 1278, 2018 | 154 | 2018 |
| Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial I Demeestere, P Brice, FA Peccatori, A Kentos, I Gaillard, P Zachee, ... J Clin Oncol 31 (7), 903-9, 2013 | 142 | 2013 |
| Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study E Van Den Neste, N Schmitz, N Mounier, D Gill, D Linch, M Trneny, ... Bone marrow transplantation 52 (2), 216-221, 2017 | 139 | 2017 |
| Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study PA Thompson, V Lévy, CS Tam, C Al Nawakil, FX Goudot, A Quinquenel, ... British journal of haematology 175 (3), 462-466, 2016 | 139 | 2016 |
| Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC–GELA H8 randomised controlled trial N Heutte, HH Flechtner, N Mounier, WAM Mellink, JH Meerwaldt, ... The lancet oncology 10 (12), 1160-1170, 2009 | 128 | 2009 |
| Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a … S Lepretre, T Aurran, B Mahé, B Cazin, O Tournilhac, H Maisonneuve, ... Blood, The Journal of the American Society of Hematology 119 (22), 5104-5110, 2012 | 118 | 2012 |
